HCC I/II update
Immunicum AB (publ) today reported an update on the safety and survival data from the ongoing phase I/II study with INTUVAX in patients with primary liver cancer. Currently, ten patients have received at least one dose of INTUVAX and an additional patient is scheduled to begin treatment before year-end. Of the seven patients who have so far received all three doses of INTUVAX, five have exhibited a prolonged survival compared to expected based on historical data. Immunicum also announces plan for an extension of the study where INTUVAX will be combined with first-line treatments.
Read the press release here: Press release 151125 – HCC I-II update and continuation
Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4977